{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:27:27Z","timestamp":1793939247554,"version":"4.8.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005688","name":"Gottfried und Julia Bangerter-Rhyner-Stiftung","doi-asserted-by":"publisher","award":["YTCR 08\/20"],"award-info":[{"award-number":["YTCR 08\/20"]}],"id":[{"id":"10.13039\/501100005688","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008485","name":"Schweizerische Akademie der Medizinischen Wissenschaften","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008485","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006447","name":"Universit\u00e4t Z\u00fcrich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030\\u2013200,669"],"award-info":[{"award-number":["310030\\u2013200,669"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.autrev.2026.104187","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:58:34Z","timestamp":1789603114000},"page":"104187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Low-dose interleukin-2 for the treatment of systemic lupus erythematosus: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"25","author":[{"given":"Roberto","family":"Colli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenios","family":"Kladis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"Boyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miro E.","family":"Raeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.autrev.2026.104187_bb0005","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"issue":"9957","key":"10.1016\/j.autrev.2026.104187_bb0010","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0140-6736(14)60128-8","article-title":"Systemic lupus erythematosus","volume":"384","author":"Lisnevskaia","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.autrev.2026.104187_bb0015","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/096120339500400202","article-title":"Serological markers of disease activity in systemic lupus erythematosus","volume":"4","author":"Spronk","year":"1995","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.autrev.2026.104187_bb0020","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/rheumatology\/kep064","article-title":"The BILAG-2004 index is sensitive to change for assessment of SLE disease activity","volume":"48","author":"Yee","year":"2009","journal-title":"Rheumatol Oxf Engl."},{"issue":"9","key":"10.1016\/j.autrev.2026.104187_bb0025","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/rheumatology\/keq026","article-title":"Numerical scoring for the BILAG-2004 index","volume":"49","author":"Yee","year":"2010","journal-title":"Rheumatol Oxf Engl"},{"issue":"6","key":"10.1016\/j.autrev.2026.104187_bb0030","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2026.104187_bb0035","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.24698","article-title":"Novel evidence-based systemic lupus erythematosus responder index","volume":"61","author":"Furie","year":"2009","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.autrev.2026.104187_bb0040","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study","volume":"73","author":"Wallace","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9767","key":"10.1016\/j.autrev.2026.104187_bb0045","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.autrev.2026.104187_bb0050","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2026.104187_bb0055","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa2516150","article-title":"Efficacy and safety of Obinutuzumab in active systemic lupus erythematosus","volume":"395","author":"Furie","year":"2026","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104187_bb0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104187_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"10.1016\/j.autrev.2026.104187_bb0070","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.molmed.2017.05.006","article-title":"Pathogenesis of human systemic lupus erythematosus: a cellular perspective","volume":"23","author":"Moulton","year":"2017","journal-title":"Trends Mol Med"},{"issue":"670","key":"10.1016\/j.autrev.2026.104187_bb0075","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo5409","article-title":"Interleukin-2-based therapies in cancer","volume":"14","author":"Raeber","year":"2022","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.autrev.2026.104187_bb0080","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","article-title":"Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus","volume":"75","author":"von Spee-Mayer","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2026.104187_bb0095","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104187_bb0205","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104187_bb0085","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104187_bb0090","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/imr.12644","article-title":"The role of cytokines in T-cell memory in health and disease","volume":"283","author":"Raeber","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2026.104187_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.648408","article-title":"Low-dose IL-2 therapy in autoimmune and rheumatic diseases","volume":"12","author":"Gra\u00dfhoff","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104187_bb0105","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.autrev.2026.104187_bb0110","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.autrev.2026.104187_bb0115","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.autrev.2026.104187_bb0120","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.autrev.2026.104187_bb0125","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024)","year":"2024"},{"key":"10.1016\/j.autrev.2026.104187_bb0130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-1-0716-1566-9_4","article-title":"Assessing heterogeneity in random-effects Meta-analysis","volume":"2345","author":"Langan","year":"2022","journal-title":"Methods Mol Biol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104187_bb0135","article-title":"Standardized mean differences in meta-analysis: a tutorial","volume":"2","author":"Gallardo-G\u00f3mez","year":"2024","journal-title":"Cochrane Evid Synth Methods"},{"issue":"1","key":"10.1016\/j.autrev.2026.104187_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.1165","article-title":"Efficacy, safety and the lymphocyte subsets changes of low-dose IL-2 in patients with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"12","author":"Su","year":"2024","journal-title":"Immun Inflamm Dis"},{"issue":"9","key":"10.1016\/j.autrev.2026.104187_bb0145","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104187_bb0150","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/S2665-9913(19)30018-9","article-title":"Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial","volume":"1","author":"Humrich","year":"2019","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104187_bb0155","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2026.104187_bb0160","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1136\/ard-2022-222501","article-title":"Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial","volume":"81","author":"Humrich","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104187_bb0165","article-title":"Low-dose IL-2 mitigates glucocorticoid-induced Treg impairment and promotes improvement of SLE","volume":"8","author":"Zhou","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.autrev.2026.104187_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103172","article-title":"The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial","volume":"144","author":"Lorenzon","year":"2024","journal-title":"J Autoimmun"},{"issue":"9","key":"10.1016\/j.autrev.2026.104187_bb0175","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.immuni.2024.07.016","article-title":"Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics","volume":"57","author":"Raeber","year":"2024","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.autrev.2026.104187_bb0180","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-024-03388-5","article-title":"Predictive biomarkers for low-dose IL-2 therapy efficacy in systemic lupus erythematosus: a clinical analysis","volume":"26","author":"Feng","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104187_bb0185","article-title":"Low dose IL-2 therapy restores regulatory T cells in patients with systemic lupus erythematosus in a dose-dependent manner: a phase IIb trial","volume":"17","author":"Zhang","year":"2026","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.autrev.2026.104187_bb0190","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/070674370204700307","article-title":"Breaking up is hard to do: the heartbreak of dichotomizing continuous data","volume":"47","author":"Streiner","year":"2002","journal-title":"Can J Psychiatry"},{"issue":"4","key":"10.1016\/j.autrev.2026.104187_bb0195","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright natural killer (NK) cells: an important NK cell subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology"},{"issue":"5","key":"10.1016\/j.autrev.2026.104187_bb0200","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41590-022-01179-1","article-title":"Dynamic transcriptional activity and chromatin remodeling of regulatory T cells after varied duration of interleukin-2 receptor signaling","volume":"23","author":"Moro","year":"2022","journal-title":"Nat Immunol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226002016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226002016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:05:24Z","timestamp":1793937924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226002016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1568997226002016"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104187","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose interleukin-2 for the treatment of systemic lupus erythematosus: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104187","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104187"}}